Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.39 |
| ▸ | BRD4 | O60885 | 8/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 6/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035864 | 0.80 | TNK2 (0.38) | JAK2BRD4JAK3PAK4PKN1 | |
| SCHEMBL15035007 | 0.78 | PAK4 (0.38) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15277151 | 0.78 | JAK3 (0.39) | JAK2BRD4RIPK2ACVR1NOD2 | |
| SCHEMBL15036088 | 0.77 | RIPK2 (0.44) | JAK2RIPK2ACVR1NOD2JAK3 | |
| SCHEMBL15035892 | 0.76 | BRD4 (0.38) | JAK2BRD4ACVR1JAK3PTK2 | |
| SCHEMBL15034918 | 0.75 | CDK4 (0.41) | JAK3FGFR1PAK4PKN1WEE1 | |
| SCHEMBL15034776 | 0.75 | PAK4 (0.37) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15237012 | 0.75 | PAK4 (0.39) | JAK2BRD4JAK3FGFR1PAK4 | |
| SCHEMBL15034877 | 0.75 | PAK4 (0.40) | JAK2BRD4JAK3FGFR1PAK4 | |
| SCHEMBL15035745 | 0.73 | RIPK2 (0.48) | RIPK2ACVR1NOD2FGFR1PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | JAK2 720/4885BRD4 1003/4885RIPK2 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.